Sell Dr. Lal PathLabs; target of Rs 895: Prabhudas Lilladher Prabhudas Lilladher is bearish on Dr. Lal PathLabs has recommended sell rating on the stock with a target price of Rs 895 in its research report dated May 19, 2020.
Opportunity is pharma is huge, advise investors to invest: Motilal Oswal As lockdown mode could continue and the government's ability to come out with an aggressive bailout package is limited, it's difficult to make out a case for big upside in the short run.
Drop airlines! Here are top 10 stocks based on Warren Buffett's investment methodology Warren Buffett once again showed investors as to how one can cut losses and preserve cash. The investing phenomenon is dynamic in nature and usually changes over a period of time based on the prevailing trend.